Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End point reduction in hypertension (LIFE) study
Angiotensin II Type 1 Receptor Blockers
Cause of Death
Hypertrophy, Left Ventricular
Losartan is more effective than atenolol-based therapy in reducing the risk of the primary composite end point of cardiovascular morbidity and mortality as well as stroke and cardiovascular death in hypertensive patients with ECG LV hypertrophy and AF.